Orthofix reports record Q4 net sales of $215.7M (+8% YoY); guides FY25 sales $818-826M, adj. EBITDA $82-86M

Orthofix Medical Inc.

2024-FY EPS reported -$3.30 revenue$799,491,000

Q4 net sales $215.7M (+8% YoY); record BGT $63.9M (+9%) and Global Orthopedics $35.8M (+18% cc).
Q4 net loss $(29.1)M ($(0.75)/share); adjusted EBITDA $23.9M (11.1% margin) vs $19.6M (9.8%) in Q4 2023.
FY24 net sales $799.5M (+7%); net loss $(126.0)M vs $(151.4)M; adjusted EBITDA $67.4M (8.4% margin) vs $46.3M.
Discontinuing M6 artificial disc lines ($23.4M 2024 sales); guides FY25 sales $818-826M (ex-M6, +6.5% cc) and adj. EBITDA $82-86M.
Long-term CAGR target raised to 6.5-7.5%; Q4 free cash flow $15.2M; cash $85.7M at year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.